- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04193670
Sensory Nociceptive Nerve Fibers, Key Regulator of Immune Response Type 2 in Atopic Dermatitis (IMMCEPTION)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Marie TAUBER
- Phone Number: +33 5 67 77 81 23
- Email: tauber.ma@chu-toulouse.fr
Study Locations
-
-
-
Toulouse, France, 31059
- CHU de Toulouse
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Criteria for the study population:
- Subject affiliated with a social security scheme or beneficiary of such a scheme;
- subject who has given written consent to participate in the study;
- Subject accepting a blood test to check for the absence of infectious diseases (HIV serologies, Hepatitis B, Hepatitis C) in the event of a blood exposure accident;
- Subject who did not apply emollient care products to the areas to be biopsied within 24 hours prior to the inclusion visit.
- Subject accepting biopsies
Criteria related to the pathology studied:
- Subject with atopic dermatitis according to UK Working Party criteria or Williams criteria with an IGA score ≥ 3 (group 1)
- Subject with atopic dermatitis according to UK Working party criteria or Williams criteria in the form of an atopic prurigo diagnosed by the dermatologist (group 2)
Criteria relating to control subjects: Subjects who had abdominoplasty and agreed to use their skin sample as part of Genoskin (Ministerial Approval # AC-2017-2897) (Group 3).
Criteria for treatment:
- Systemic treatments for AD (including phototherapy) or biotherapies interrupted at least 4 weeks before the inclusion visit;
- Topical treatments: topical corticosteroids and tacrolimus stopped on the biopsied area at least 7 days before the inclusion visit.
Exclusion Criteria:
Criteria for the study population:
- Solar exposure of biopsied areas planned during the study;
- Subject having had exposure to solar radiation or artificial UV within 2 weeks before inclusion in biopsied areas.
Criteria related to the pathology studied:
- Chronic inflammatory dermatosis other than classical AD or atopic prurigo at sites to be harvested;
- Subject with a known history of allergy or intolerance to local anesthetics, local antiseptics to latex or plaster;
- Subject already having abnormalities of healing
- Subject with a recognized addiction to alcoholism or drug addiction;
- Subject having an inherited or acquired disease of hemostasis;
- Subject having a severe or acute chronic condition deemed by the investigator to be inconsistent with the trial;
- Subject with immunodeficiency clinically incompatible with the study.
Criteria for treatment:
- Any topical or systemic treatment of AD (including phototherapy) in progress
- Treatment likely to act on the haemostasis (example: anticoagulants, antiaggregating platelet ...) in the 4 weeks preceding the inclusion and during the study;
- General corticosteroids in the 4 weeks prior to the inclusion visit
- ongoing systemic treatment that may interfere with the healing process;
- Subject having undergone a physical treatment (radiotherapy, ...) on the area to be biopsied, during the last 6 months.
- History of treatment or concomitant treatment that may interfere with the completion of the study according to the opinion of the investigator.
Criteria for regulation:
- Subject unable to comply with protocol requirements;
- Subject in linguistic or psychic incapacity to sign informed consent;
- Subject being in a period of exclusion during which he can not participate in any other biomedical research;
- Subject participating in another biomedical research;
- Subject deprived of liberty by judicial or administrative decision, under guardianship, curatorship or safeguard of justice;
- Person with severely impaired physical and / or psychological health who, according to the investigator, may affect participation in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Atopic dermatitis classical form
15 patients
|
This is a classic dermatological clinical examination during a classic consultation
2 skin biopsies on a lesion area selected according to the inclusion criteria (2 punchs of 4 mm) for each experimental group. The first half of whole cutaneous biopsies (n = 25) will be studied using biphotonic microscopy. This will be performed on whole biopsies in 3-D according to the protocol developed in the laboratory. The second half of whole skin biopsies (n = 25) will be studied using the technique of single-cell RNA seq. The skin controls skin-free subjects will be obtained from skin reduction surgery (abdominoplasty) to subjects who have agreed to the use of their skin sample.
A blood test on a tube (2 tubes of 10 mL).An assay of specific IgE and the serum level of IL-4, IL-13 and IL-5 will be carried out by ELISA (Enzyme Linked ImmunoSorbent Assay) from the blood samples.The blood samples will be obtained through the French blood establishment from different donors who have given their consent.
|
Experimental: Atopic dermatitis with atopic prurigo type
10 patients
|
This is a classic dermatological clinical examination during a classic consultation
2 skin biopsies on a lesion area selected according to the inclusion criteria (2 punchs of 4 mm) for each experimental group. The first half of whole cutaneous biopsies (n = 25) will be studied using biphotonic microscopy. This will be performed on whole biopsies in 3-D according to the protocol developed in the laboratory. The second half of whole skin biopsies (n = 25) will be studied using the technique of single-cell RNA seq. The skin controls skin-free subjects will be obtained from skin reduction surgery (abdominoplasty) to subjects who have agreed to the use of their skin sample.
A blood test on a tube (2 tubes of 10 mL).An assay of specific IgE and the serum level of IL-4, IL-13 and IL-5 will be carried out by ELISA (Enzyme Linked ImmunoSorbent Assay) from the blood samples.The blood samples will be obtained through the French blood establishment from different donors who have given their consent.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Characterization of neuronal interactions by two-photon microscopy
Time Frame: 13 months
|
quantification by two-photon microscopy of the density of nerve fibers producing SP, the density of MRGPRX2 + MCs, the spatial proximity between nerve fibers and MC and quantification of the degranulated appearance of MC in the lesional skin of patients with DA classical form and DA atopic prurigo type in comparison to the skin of control subjects.
|
13 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Marker analysis by ELISA assay
Time Frame: 13 months
|
Analyze the intensity of type 2 immunity markers (Specific IgE Assay for Dermatophagoids Farinae, IL-4, IL-13 and IL-5) in the blood of patients with classical AD and atopic prurigo type AD.
|
13 months
|
Cellular analysis
Time Frame: 13 months
|
To analyze the diversity of cellular subtypes present in the skin of patients with classical AD and atopic prurigo type DA.
|
13 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Marie TAUBER, University Hospital, Toulouse
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RC31/19/0118
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atopic Dermatitis
-
Catalysis SLCompletedAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related Conditions | Atopic Dermatitis \(AD\)Serbia
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis FlareDenmark
-
ShaperonNot yet recruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis of Scalp
-
University of California, San FranciscoSanofi; Regeneron PharmaceuticalsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related ConditionsUnited States
-
PfizerActive, not recruitingEczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, UnspecifiedUnited States, Canada, Czechia, Poland
-
AmgenCompletedDermatitis, Atopic DermatitisCanada, United States, Japan
-
Hadassah Medical OrganizationUnknownATOPIC DERMATITIS
-
SanofiCompletedAtopic Dermatitis | Dermatitis AtopicChina
-
SanofiCompletedDermatitis AtopicSaudi Arabia, Kuwait, United Arab Emirates
-
National Institute of Allergy and Infectious Diseases...Atopic Dermatitis Research NetworkCompletedAtopic Dermatitis (AD) | Non-atopic Healthy ControlsUnited States
Clinical Trials on Clinical examination
-
University Hospital, Basel, SwitzerlandDePuy SynthesRecruitingArthroscopic Rotator Cuff Repair (ARCR)Switzerland
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationRecruiting
-
Cukurova UniversityCompletedSurvival, Prosthesis | Clinical Acceptability, ProsthesisTurkey
-
Bezmialem Vakif UniversityThe Scientific and Technological Research Council of Turkey; Abant Izzet Baysal... and other collaboratorsCompleted
-
University Hospital, AkershusCompletedCongenital Heart DiseaseNorway
-
Cairo UniversityUnknown
-
CHU de ReimsCompletedErosive Pustular Dermatosis of the LegFrance
-
St. Olavs HospitalNational Taiwan Normal UniversityRecruiting
-
AspetarUniversity College DublinCompletedHip Pain Chronic | Inguinal Hernia | Groin Injury | Iliopsoas Syndrome | Adductor TendinitisQatar